At the 2025 Urology On The Beach meeting, Jose A. Karam, MD, FACS, from the Department of Urology at The University of Texas MD Anderson Cancer Center, explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery, as well as the importance of accurate imaging when making these decisions. He also comments on how best to counsel patients with small renal masses on choosing active surveillance rather than surgery. ...
Renal Cell Carcinoma Diagnostics
Advertisement
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Machine learning models can help with clinical decision making regarding renal function, according to new data.
[⁸⁹Zr]Zr-girentuximab PET-CT ccRCC prognostic imaging has a favorable safety profile and is highly accurate.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. Advertisement
Video Insights
Conferene Coverage
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.